aids research and reference reagent program

HIV and AIDS Research Resources

In addition to funding research on HIV/AIDS and HIV-malignancies, the NCI makes a number of resources available to investigators working in this area. Listed below is information on several useful resources provided by the NCI that are specific to research in HIV/AIDS and HIV-associated malignancies. Also listed are links to general resources provided by the NCI that may be of use to HIV/AIDS researchers, as well as selected resources provided by other components of the NIH.

NCI HIV/AIDS and AIDS Malignancy Resources

Aids and cancer specimen resource (acsr).

The ACSR, which is funded by OHAM, is a biorepository of HIV-infected human biospecimens, including tissues and biological fluids, obtained from a wide spectrum of HIV-related or associated diseases.

Information on compounds screened in the NCI in vitro anti-HIV screen

From 1987 through 1997, the Developmental Therapeutics Program (DTP) of the NCI maintained an anti-HIV screening program and screened many compounds, including many natural products. A repository of information on screening data and the chemical structures of the compounds screened are found on the DTP Website.

Reagents and Analytic Capabilities in the AIDS and Cancer Vaccine Program

Various reagents and analytical capabilities relevant to AIDS research are available through the AIDS and Cancer Virus Program at NCI Frederick. You can contact Tricia Grove ( [email protected] ; 301 846 1408) for more information.

Related NCI Resources

Directory of resources available from the nci.

A directory of a broad array of tools and research services for cancer researchers is found at the NCI Research Resources Website .

The NCI Biological Resources Branch (BRB) Repository

The BRB Preclinical Repository is an NCI-sponsored facility that contains bulk cytokines, monoclonal antibodies, cytokine standards, and other research reagents that are maintained under carefully controlled storage conditions. The purpose of this facility is to maintain and distribute a constant and uniform supply of high quality reagents for scientists at non-profit as well as commercial establishments.

Surveillance, Epidemiology and End Results (SEER) Program

SEER collects information on incidence, survival, and prevalence from specific geographic areas representing 26 percent of the US population. Information on these cancer statistics can be found on the SEER Website .

NIH Resources of Interest to HIV/AIDS Researchers

Nih aids research and reference reagent program.

This program, created by the National Institute of Allergy and Infectious Diseases (NIAID), provides state-of-the-art biological and chemical materials for the study of HIV and related opportunistic pathogens to registered users worldwide at no cost. Find more information about this NIH AIDS Research and Reference Reagent Program .

National Center for Research Resources (NCRR)

NCRR , part of the NIH, provides laboratory scientists and clinical researchers with a variety of tools and training resources.

NIAID HIV Protein Interaction Database

The NIAID Protein Interaction Database provides a summary of known interactions of HIV proteins with host cell proteins, other HIV proteins, or proteins from disease organisms associated with HIV/AIDS.

Retrovirus Genome Database

The National Center for Biotechnology Information (NCBI) has a database of retrovirus genomes and related resources, such as the HIV structural database, a listing of anti-HIV compounds, and the Stanford HIV drug resistance database. Access the Retrovirus Genome Database .

• Remote Access

NIH AIDS Research and Reference Reagent Program

• The Web site provides information on reagents for studying HIV and related opportunistic infections.
• It also allows researches to order these reagents directly on line.
• The NIH AIDS Reagent Program evolved from a small bank of HIV research materials into a unique worldwide resource of state-of-the art reagents for HIV and other pathogens. Many of these reagents are not commercially available.
• Reagents currently in development include: unique overlapping peptide sets for: HIV-1, SIV (consensus M Gag, and Nef; subtype C consensus and ancestral Env and Gag; SIVAGM Env, Gag and Tat); CMV peptide pool for intracellular cytokine assay; sexually acquired HIV-1 of various subtypes during early stages of virus transmission; standard panels of HIVs, SIVs, and SHIVs for vaccine neutralization studies; and macaque specific monoclonal antibodies to CD4, CD8, NK cells and perforin.
• AIDS reagent
• HIV reagent
• HIV overlapping peptide sets
• HIV-1 subtypes
• AIDS macaque specific monoclonal antibodies

The Health Sciences Library System supports the Health Sciences at the University of Pittsburgh .

© 1996 - 2023 Health Sciences Library System, University of Pittsburgh. All rights reserved.

NIH-AIDS Research and Reference Reagent Program Matocha, Martha F.    Fisher Bioservices, Inc., Rockville, MD, United States

• Institution
• Related projects

 Recent in Grantomics:

• Your institution vs. funders. Who wins? Read more...
• How should you pick the next fundable research topic? Read more...

 Recently viewed grants:

• Signaling circuits that drive cell movement and ligand scavenging by chemokine receptor CCR2
• Targeting the developmental pathways Notch and ERBB for melanoma therapy
• Dysregulation of Glucose Homeostasis in Aging
• Transport Characteristics in Specific Renal Cell Types
• STTR Phase I: Development of Sugar Beet Pulp Enzymatic Pretreatment System

 Recently added grants:

• Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy
• Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer
• Defining the contributions of BRCA1, BRCA2, and RAD52 to genome stability
• Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR
• Radiotherapy-associated breast cancer: machine learning on genotypes to predict individualized risk

  Abstract

The objective of AIDS Reagent Program is to acquire and distribute critical reagents for HIV/AIDS research including opportunistic infection studies and TB. The Reagent Program produces these reagents, standardized panels, and protocols; and provides them free of charge to investigators worldwide. Additionally, the reagent program collects information about AIDS-related reagents and standards and disseminates this information through print, electronic media, and wet workshops; enhances technology transfer through development and publication of methods; and facilitates commercial development of reagents through proactive communication with biotechnology and pharmaceutical companies; and participates as an AIDS Collaborating Center of UNAIDS and United Kingdom's MRC AIDS Reagent Project. The Reagent Program also provides technical assistance in handling and shipping of infectious materials. Available reagents include: genotyped clinical and laboratory isolates of viruses, cell lines, genetic clones, DNA libraries, expression vectors, monoclonal and polyclonal antibodies, recombinant proteins, synthetic peptides, reference panels including PCR standards, body fluids, and drug standards. Since its establishment in 1988, the Reagent Program has evolved from a small bank of research materials to a unique resource. Contributors and users include scientists from the NIH, academic and non-profit institutions, and from industry. Since 1988, over 50,000 reagents have been distributed and more than 1,300 scientific publications have a referenced use of materials obtained from the Program. The success of the Program is further evident in the expanding network of users. Over 1400 scientists from 39 countries in North and South America, Europe, Asia, Africa, and Australia have registered and obtained reagents from the Program.

  Funding Agency

  institution,   related projects,   comments.

• Even more »

Account Options

• Try the new Google Books
• Advanced Book Search
• Download EPUB
• Download PDF

Get this book in print

• On Demand Books
• Find in a library
• All sellers  »

Selected pages

Common terms and phrases

Bibliographic information.

HIV Research Program (HRP)

NIDA's HIV Research Program (HRP, formerly the AIDS Research Program) supports the development, planning, and coordination of high priority research at the intersection of HIV, substance use, and substance use disorders, working across the federal government and with communities. Get more information about the Program

• NIDA HIV/AIDS Research Priorities
• HIV/AIDS Program Contacts
• HRP Staff List

NIDA HIV Seminar Series - Social and Political Determinants of HIV among People Who Use Drugs

Join Dr. Bluthenthal of the University of Southern California to discuss research at the intersection of substance use...

At the Intersection: HIV & Substance Use Research

Hear the latest approaches in treatment and care from experts in the fields of HIV and SUD in this NIDA video series

Avant-Garde Award Program for HIV and Substance Use Disorder Research

Supports individual scientists of exceptional creativity at all career levels who propose high-impact research

Avenir Awards for HIV Research

NIDA’s Avenir Awards provide grants to early stage investigators who propose highly innovative studies.

Program Links

About the HIV Research Program

About the HRP - Mission, Research Priorities, Funding Priorities, Training Opportunities, Staff Lists

HIV/AIDS Funding Opportunities

Funding opportunities related to the HIV Research Program

Guidance for Potential Applicants of NIDA HIV Avant-Garde (DP1) and Avenir (DP2) Programs

Learn more about the HIV Avant-Garde or Avenir Awards and find tips to improve your application.

HRP Meetings of Interest

Meetings of interest to the HIV/AIDS research community

Messages from the NIDA HRP Team

Messages from the HRP scientific leadership team on interesting new findings in the field and funding opportunities.

NIH-AIDS Research and Reference Reagent Program Matocha, Martha F.    Ogden Bioservices Corporation, Gaithersburg, MD, United States

• Institution
• Related projects
• Publications

 Recent in Grantomics:

• Your institution vs. funders. Who wins? Read more...
• How should you pick the next fundable research topic? Read more...

 Recently viewed grants:

• Signaling circuits that drive cell movement and ligand scavenging by chemokine receptor CCR2
• Targeting the developmental pathways Notch and ERBB for melanoma therapy
• Dysregulation of Glucose Homeostasis in Aging
• Transport Characteristics in Specific Renal Cell Types
• STTR Phase I: Development of Sugar Beet Pulp Enzymatic Pretreatment System

 Recently added grants:

• Development of Next Generation Galeterone Analogs for Prostate Cancer Therapy
• Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer
• Defining the contributions of BRCA1, BRCA2, and RAD52 to genome stability
• Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR
• Radiotherapy-associated breast cancer: machine learning on genotypes to predict individualized risk

  Abstract

The NIH AIDS Research and Reference Reagent Program (Repository) established by the NIAID in 1988 is a unique resource. It acquires critically needed reagents for AIDS-related research (i.e., samples of cell lines, HIV and related viruses, opportunistic infectious agents associated with HIV infections, DNA libraries, DNA clones, antibodies, purified proteins, synthetic peptides, body fluids, and reference standards), and provides these reagents free of charge to qualified investigators worldwide. The Repository encourages collaborative research aimed at standardizing reagents and laboratory techniques. The Repository is a AIDS Collaborating Center of the World Health Organization. Most of the reagents in the Repository are donated and the generosity of donors is gratefully acknowledged. Any commercial use of reagents requires written permission and compensation of reagent donor(s) and notification of the Repository. Contributors of reagents and users of the Repository include scientists from the NIH, academic and non- profit institutions, and from the private sector. Currently, the Repository has 500 registered users of its services and increasing numbers of investigators are citing the reagent donors and Repository as a source of essential reagents in their publications. During the past five years the Repository has provided more than 17,000 reagents to AIDS investigators worldwide. Repository catalogs published, yearly, contain descriptions of reagents, reagent contributors, biological safety information, vendors of AIDS research reagents, and forms necessary to receive and information to contribute reagents. Updates of catalog are provided periodically in the Repository's newsletter.

  Funding Agency

  institution,   related projects,   publications,   comments.

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1

Affiliations.

• 1 Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
• 2 Kaiser-Permanente Medical Care Program-Northern California, San Francisco, California, USA.
• 3 Department of Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, Massachusetts, USA.
• 4 Department of Statistics, Stanford University, Stanford, California, USA.
• 5 Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA [email protected].
• PMID: 23796938
• PMCID: PMC3754322
• DOI: 10.1128/AAC.00614-13

The many genetic manifestations of HIV-1 protease inhibitor (PI) resistance present challenges to research into the mechanisms of PI resistance and the assessment of new PIs. To address these challenges, we created a panel of recombinant multi-PI-resistant infectious molecular clones designed to represent the spectrum of clinically relevant multi-PI-resistant viruses. To assess the representativeness of this panel, we examined the sequences of the panel's viruses in the context of a correlation network of PI resistance amino acid substitutions in sequences from more than 10,000 patients. The panel of recombinant infectious molecular clones comprised 29 of 41 study-defined PI resistance amino acid substitutions and 23 of the 27 tightest amino acid substitution clusters. Based on their phenotypic properties, the clones were classified into four groups with increasing cross-resistance to the PIs most commonly used for salvage therapy: lopinavir (LPV), tipranavir (TPV), and darunavir (DRV). The panel of recombinant infectious molecular clones has been made available without restriction through the NIH AIDS Research and Reference Reagent Program. The public availability of the panel makes it possible to compare the inhibitory activities of different PIs with one another. The diversity of the panel and the high-level PI resistance of its clones suggest that investigational PIs active against the clones in this panel will retain antiviral activity against most if not all clinically relevant PI-resistant viruses.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Grants and funding

• R01 AI046148/AI/NIAID NIH HHS/United States
• R01 AI068581/AI/NIAID NIH HHS/United States
• R56 AI068581/AI/NIAID NIH HHS/United States